Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes specially designed nanoparticles, particularly gold-based, that are functionalized with chemical groups (such as polyhydroxylated and/or sulfated compounds) to specifically inhibit selectin-mediated cell adhesion. Selectins are molecules that are involved in the process whereby white blood cells interact with blood vessel walls, an important step in the inflammatory response. By blocking this interaction with high affinity, these nanoparticles can act as effective anti-inflammatory therapeutics for treating various inflammatory diseases.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of chronic inflammatory diseases such as rheumatoid arthritis, asthma, and psoriasis.
• Prevention or reduction of tissue damage in ischemia-reperfusion injury (e.g. following stroke, heart attack, or organ transplantation).
• Reducing graft rejection in organ transplantation by limiting leukocyte infiltration.
• Development as a platform for other targeted anti-inflammatory or immunomodulatory therapies.
• Diagnostic tools or imaging agents for inflammation sites, due to their selectivity for selectin interactions.

BenefitsContent extracted from patent full text and abstract with AI.

• Offers high-affinity inhibition of selectin-mediated cell adhesion, with greater potency than existing inhibitors.
• Potential for targeted therapy, reducing systemic side effects often seen in conventional anti-inflammatory drugs.
• Nanoparticles have high stability in physiological environments and are resistant to metabolic or hydrolytic breakdown.
• Versatile synthesis allows customization of surface chemistry for different therapeutic needs.
• Could address currently unmet medical needs, such as refractory chronic inflammation or prevention of graft rejection.
• May lower required dosages due to picomolar efficacy, improving safety and patient compliance.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to functionalized nanoparticles inhibiting selectin-mediated cell adhesion and their use as anti-inflammatory therapeutics.